课题基金 / 基金详情

Hypoxia, Latency and Reactivation in M.tuberculosis

Hypoxia, Latency and Reactivation in M.tuberculosis
结核分枝杆菌的缺氧、潜伏期和再激活
批准号:
6857094
负责人:
DAVID R SHERMAN
金额:
$33.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-15 至 2007-02-28

项目摘要

项目成果

DAVID R SHERMAN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by the applicant): Central to the pathogenic success of Mycobacterium tuberculosis (MTB) is its ability to persist within humans for long periods in a latent state, without causing any overt disease symptoms. Roughly one-third of the world population harbors latent MTB, greatly complicating efforts at tuberculosis control. A person with latent tuberculosis has about a 10 percent lifetime chance of developing active disease, and when such a person contracts HIV, the risk of developing reactivation TB increases to 8 - 10 percent per year. Hypoxic conditions within the human host are widely regarded as crucial for development of latent tuberculosis, but the MTB adaptive response to hypoxia is at present very poorly understood. The goal of this proposal is to define the MTB hypoxic response as it relates to latency and reactivation. We will mechanistically dissect this response and analyze the role of hypoxia in latent tuberculosis and reactivation. This proposal will define the genes whose response to reduced oxygen tension comprises the MTB hypoxia regulon. We will also focus on MTB alpha-crystallin (Acr), a component of the hypoxic response that is powerfully induced by microaerophilic conditions. We will determine the specific conditions in which expression of alpha-crystallin and its regulators is necessary for achieving latency or reactivation. Finally, we will dissect the alpha-crystallin regulatory machinery to determine the precise mechanisms by which oxygen tension controls MTB gene expression. The result will be better tools to confront the threat to more than one billion persons with latent tuberculosis, millions of whom are now or will soon be co-infected the the human immunodeficiency virus, HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis
  • 批准号:
    10117593
  • 项目类别:
  • 资助金额:
    $73.08万
  • 财政年份:
    2021
  • 负责人:
    DAVID R SHERMAN
  • 依托单位:
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
  • 批准号:
    10493290
  • 项目类别:
  • 资助金额:
    $14.37万
  • 财政年份:
    2021
  • 负责人:
    DAVID R SHERMAN
  • 依托单位:
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis
  • 批准号:
    10669196
  • 项目类别:
  • 资助金额:
    $72.12万
  • 财政年份:
    2021
  • 负责人:
    DAVID R SHERMAN
  • 依托单位: